Abstract
The α1-adrenoceptors (α1-ARs) are involved in regulation of prostatic smooth muscle tone, and are a critical mediator of lower urinary tract symptoms and pathophysiology in benign prostatic hyperplasia (BPH). As a result, α1-AR antagonists are now used as first-line medical treatment for BPH. Three α1-AR subtypes (α1a-AR, α1b-AR, α1d-AR) have been identified on the basis of results of pharmacological and molecular cloning studies; however, the precise physiological role of individual α1-AR subtypes remains elusive. The expression levels of α1-AR subtypes in the prostate differ between patients, and individual differences in the genetic background of patients with BPH might be associated with variation in responses to subtype-selective α1-AR antagonists. In addition, single nucleotide polymorphism and microarray-based gene expression profiling studies might provide an opportunity to identify markers that predict clinical response and therapeutic tolerance to α1-AR antagonists. Further genomic studies will refine our knowledge of the functions of α1-AR subtypes, lead to new strategies for the clinical management of BPH and, perhaps, enable personalized treatment of BPH in the future.
Key Points
-
The α1-adrenoceptors (α1-ARs) have a major role in the regulation of prostatic smooth muscle tone, and are critical mediators of lower urinary tract symptoms and pathophysiology in benign prostatic hyperplasia (BPH)
-
Thus, α1-AR antagonists are now often used as first-line medical treatment for patients with BPH-associated lower urinary tract symptoms
-
Studies of α1-ARs have provided clues as to subtype-specific physiological function, and response to α1-AR antagonists
-
Molecular genetic approaches, such as genomics, transcriptomics, proteomics and metabolomics, might provide an opportunity to identify predictive markers of clinical response to α1-AR antagonists, and could perhaps enable personalized treatment of BPH in the future
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Roehrborn CG and Schwinn DA (2004) α1-Adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 171: 1029–1035
Koshimizu TA et al. (2004) Recent advances in α1-adrenoceptor pharmacology. Pharmacol Ther 98: 235–244
Hieble JP et al. (1995) International Union of Pharmacology. X. Recommendation for nomenclature of α1-adrenoceptors: consensus update. Pharmacol Rev 47: 267–70
Price DT et al. (1993) Identification, quantification, and localization of mRNA for three distinct α1 adrenergic receptor subtypes in human prostate. J Urol 150: 546–551
Price DT et al. (1994) Localization of mRNA for three distinct α1-adrenergic receptor subtypes in human tissues: implications for human α-adrenergic physiology. Mol Pharmacol 45: 171–175
Rudner XL et al. (1999) Subtype specific regulation of human vascular α1-adrenergic receptors by vessel bed and age. Circulation 100: 2336–2343
Andersson KE and Gratzke C (2007) Pharmacology of α1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 4: 368–378
Andersson KE (2007) LUTS treatment: future treatment options. Neurourol Urodyn 26 (Suppl 6): S934–S947
Tanoue A et al. (2003) Insights into α1 adrenoceptor function in health and disease from transgenic animal studies. Trends Endocrinol Metab 14: 107–113
Faure C et al. (1994) Identification of α1-adrenoceptor subtypes present in the human prostate. Life Sci 54: 1595–1605
Nasu K et al. (1996) Quantification and distribution of α1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 119: 797–803
Overbergh L et al. (2003) The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J Biomol Tech 14: 33–43
Juhasz A et al. (2003) Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription–PCR vs relative quantification reverse transcription–PCR utilizing DNA sequencer analysis of PCR products. J Clin Lab Anal 17: 184–194
Kojima Y et al. (2006) Quantification of α1-adrenoceptor subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients. Prostate 66: 761–767
Lepor H et al. (1995) Localization of the α1a-adrenoceptor in the human prostate. J Urol 154: 2096–2099
Michel MC et al. (1996) Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned α1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol 16: 21–28
Michel MC and Vrydag W (2006) α1-, α2- and β-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 47 (Suppl 2): S88–S119
Walden PD et al. (1999) Localization and expression of the α1a-1, α1b and α1d-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol 161: 635–640
Lepor H et al. (1993) The α-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate 22: 301–307
Forray C et al. (1994) The α1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human α1c subtype. Mol Pharmacol 45: 703–708
Andersson KE (2002) α-Adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with α-adrenoceptor antagonists. World J Urol 19: 390–396
Ikegaki I et al. (2000) Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia [Japanese]. Nippon Yakurigaku Zasshi 116: 63–69
Takei R et al. (1999) Naftopidil, a novel α1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α1-adrenoceptors. Jpn J Pharmacol 79: 447–454
Gotoh M et al. (2005) Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU Int 96: 581–586
Nishino Y et al. (2006) Comparison of two α1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int 97: 747–751
Schwinn DA and Michelotti GA (2000) α1-Adrenergic receptors in the lower urinary tract and vascular bed: potential role for the α1d subtype in filling symptoms and effects of ageing on vascular expression. BJU Int 85 (Suppl 2): S6–S11
Malloy BJ et al. (1998) α1-Adrenergic receptor subtypes in human detrusor. J Urol 160: 937–943
Muramatsu I et al. (1994) Pharmacological characterization of α1-adrenoceptor subtypes in the human prostate: functional and binding studies. Br J Urol 74: 572–578
Morishima S et al. (2007) Identification of α1L and α1a adrenoceptors in human prostate by tissue segment binding. J Urol 177: 377–381
Hayase M et al. (2008) Mechanisms of human prostate smooth muscle spontaneous contraction. J Urol 179 (Suppl 4): S454–S455
Exintaris B et al. (2002) Spontaneous slow wave and contractile activity of the guinea pig prostate. J Urol 168: 315–322
Zhong H and Minneman KP (1999) α1-Adrenoceptor subtypes. Eur J Pharmacol 375: 261–276
Milano CA et al. (1994) Myocardial expression of a constitutively active α1b-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 91: 10109–10113
Kyprianou N (2003) Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 169: 1520–1525
Kojima Y et al. (2008) Role of α1-adrenoceptor subtype in prostatic growth in a benign prostatic hyperplasia model rat [abstract #1316]. J Urol 179 (Suppl 4): S451
Kanda H et al. (2008) Naftopidil, a selective α1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. Int J Cancer 12: 444–451
Garrison JB and Kyprianou N (2006) Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res 66: 464–472
McConnell JD et al. (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387–2398
Shibata K et al. (2003) α1-Adrenergic receptor subtypes differentially control the cell cycle of transfected CHO cells through a cAMP-dependent mechanism involving p27Kip1 . J Biol Chem 278: 672–678
Keffel S et al. (2000) α1-adrenoceptor subtypes differentially couple to growth promotion and inhibition in Chinese hamster ovary cells. Biochem Biophys Res Commun 272: 906–911
Oda N et al. (2003) New experimental model for benign prostate hyperplasia, stromal hyperplasia in rodents [abstract]. J Urol 169 (Suppl 4): S279
Caine M et al. (1978) A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 50: 551–554
Lepor H et al. (1992) A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148: 1467–1474
Gillenwater JY et al. (1995) Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 154: 110–115
Kirby R et al. (2000) α1-Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. Prostate Cancer Prostatic Dis 3: 76–83
Cavalli A et al. (1997) Decreased blood pressure response in mice deficient of the α1b-adrenergic receptor. Proc Natl Acad Sci USA 94: 11589–11594
Vecchione C et al. (2002) Cardiovascular influences of α1b-adrenergic receptor defect in mice. Circulation 105: 1700–1707
Langer SZ (1999) History and nomenclature of α1-adrenoceptors. Eur Urol 36 (Suppl 1): S2–S6
Chapple CR et al. (1996) Tamsulosin, the first prostate-selective α1a-adrenoceptor antagonist: a meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 29: 155–167
Kawabe K et al. (2006) Silodosin, a new α1 a-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98: 1019–1024
Michel MC (2007) α1-Adrenoceptors and ejaculatory function. Br J Pharmacol 152: 289–290
Kenny BA et al. (1996) Evaluation of the pharmacological selectivity profile of α1 adrenoceptor antagonists at prostatic α1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol 118: 871–878
Roehrborn CG (2001) Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 58: 953–959
McKeage K and Plosker GL (2002) Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 62: 633–653
Koshimizu TA et al. (2007) Clinical implications from studies of α1 adrenergic receptor knockout mice. Biochem Pharmacol 73: 1107–1112
Chen Q et al. (2005) Function of the lower urinary tract in mice lacking α1d-adrenoceptor. J Urol 174: 370–374
Sanbe A et al. (2007) α1-Adrenoceptors are required for normal male sexual function. Br J Pharmacol 152: 332–340
Gray KT et al. (2008) The α1a-adrenoceptor gene is required for the α1L-adrenoceptor-mediated response in isolated preparations of the mouse prostate. Br J Pharmacol 155: 103–109
Vivekanandan P and Singh OV (2008) High-dimensional biology to comprehend hepatocellular carcinoma. Expert Rev Proteomics 5: 45–60
Romero R et al. (2008) The use of high-dimensional biology (genomics, transcriptomics, proteomics, and metabolomics) to understand the preterm parturition syndrome. BJOG 113 (Suppl 3): S118–S135
Ikemoto I et al. (2003) Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study. Int J Urol 10: 587–594
Marsh S (2007) Pharmacogenomics. Ann Oncol 18 (Suppl 9): S24–S28
Singh A (2007) Pharmacogenomics—the potential of genetically guided prescribing. Aust Fam Physician 36: 820–824
Giacomini KM et al. (2007) The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 81: 328–345
Mushiroda T et al. (2006) Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet 51: 249–253
Drysdale CM et al. (2000) Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 97: 10483–10488
Koo SH and Lee EJ (2006) Pharmacogenetics approach to therapeutics. Clin Exp Pharmacol Physiol 33: 525–532
Flordellis C et al. (2004) Pharmacogenomics of adrenoceptors. Pharmacogenomics 5: 803–817
Hawrylyshyn KA et al. (2004) Update on human α1-adrenoceptor subtype signaling and genomic organization. Trends Pharmacol Sci 25: 449–455
Hoehe MR et al. (1992) A two allele PstI RFLP for the α1c adrenergic receptor gene (ADRA1C). Hum Mol Genet 1: 349
Shibata K et al. (1996) α1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy. Br J Pharmacol 118: 1403–1408
Sofowora GG (2004) α1a-adrenergic receptor polymorphism and vascular response. Clin Pharmacol Ther 75: 539–545
Mochtar CA et al. (2006) Polymorphisms in the α1a-adrenoceptor gene do not modify the short- and long-term efficacy of α1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. BJU Int 97: 852–855
Lei B et al. (2005) Novel human α1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function. Naunyn Schmiedebergs Arch Pharmacol 371: 229–239
Sadée W and Dai Z (2005) Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 14: R207–R214
Fan JB et al. (2006) Highly parallel genomic assays. Nat Rev Genet 7: 632–644
Hao K et al. (2008) Calibrating the performance of SNP arrays for whole-genome association studies. PLoS Genet 4: e1000109
Kojima Y et al. (2008) Expression of α1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective α1-adrenoceptor antagonists in the management of benign prostatic hyperplasia. J Urol 179: 1040–1046
Chen JJ (2007) Key aspects of analyzing microarray gene-expression data. Pharmacogenomics 8: 473–482
Prakash K et al. (2002) Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci USA 99: 7598–7603
Luo J et al. (2002) Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 51: 189–200
Vincent J et al. (1992) Pharmacological tolerance to α1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest 90: 1763–1768
Foster HE Jr et al. (2004) Effects of chronic administration of doxazosin on α1-adrenoceptors in the rat prostate. J Urol 172: 2465–2470
Kojima Y et al. (2007) Change of expression levels of α1-adrenoceptor subtypes by administration of α1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients. Prostate 67: 1285–1292
Yono M et al. (2005) Molecular classification of doxazosin-induced alterations in the rat prostate using gene expression profiling. Life Sci 77: 470–479
Acknowledgements
This work was supported in part by research grants from the Scientific Fund of the Japan Health Science Foundation, Grants-in-Aid 19659416 from the Japanese Ministry of Education, Culture, Science and Technology and the Japanese Foundation for Prostate Research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Kojima, Y., Sasaki, S., Hayashi, Y. et al. Subtypes of α1-adrenoceptors in BPH: future prospects for personalized medicine. Nat Rev Urol 6, 44–53 (2009). https://doi.org/10.1038/ncpuro1276
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro1276
This article is cited by
-
Identification of transcription factors potential related to brown planthopper resistance in rice via microarray expression profiling
BMC Genomics (2012)
-
Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia
BMC Urology (2012)
-
Molecular Basis of α1-AR and its Clinical Application in Male LUTS Medical Therapy
Current Bladder Dysfunction Reports (2012)